Home Cell Cycle CDK inhibitor - GSK-3 inhibitor - Apoptosis related activator - Caspase activator Alsterpaullone For research use only.

Alsterpaullone

Synonyms: Alp, 9-Nitropaullone, NSC 705701

Alsterpaullone (Alp, 9-Nitropaullone, NSC 705701) is a potent inhibitor of CDK with IC50 of 35 nM, 15 nM, 200 nM and 40 nM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E and CDK5/p35, respectively. Alsterpaullone also acts as a potent inhibitor of glycogen synthase kinase-3 (GSK-3) with IC50 of both 4 nM for GSK-3α and GSK-3β. Alsterpaullone induces apoptosis by activation of caspase-9. Alsterpaullone has antitumor activity and possesses potential for the treatment of neurodegenerative and proliferative disorders.

Alsterpaullone Chemical Structure

Alsterpaullone Chemical Structure

CAS No. 237430-03-4

Purity & Quality Control

Batch: S035401 DMSO]25 mg/mL]false]Water]Insoluble]false]Ethanol]Insoluble]false Purity: 99.81%
99.81

Alsterpaullone Related Products

Signaling Pathway

CDK Signaling Pathways

CDK Signaling Pathway

Biological Activity

Description Alsterpaullone (Alp, 9-Nitropaullone, NSC 705701) is a potent inhibitor of CDK with IC50 of 35 nM, 15 nM, 200 nM and 40 nM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E and CDK5/p35, respectively. Alsterpaullone also acts as a potent inhibitor of glycogen synthase kinase-3 (GSK-3) with IC50 of both 4 nM for GSK-3α and GSK-3β. Alsterpaullone induces apoptosis by activation of caspase-9. Alsterpaullone has antitumor activity and possesses potential for the treatment of neurodegenerative and proliferative disorders.
Targets
caspase-9 [2] GSK-3α [1]
(Cell-free assay)		 GSK-3β [1]
(Cell-free assay)		 CDK2/cyclin A [1]
(Cell-free assay)		 CDK1/cyclin B [1]
(Cell-free assay)		 Click to View More Targets
4 nM 4 nM 15 nM 35 nM
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03160430 Not yet recruiting
Kidney Failure Chronic
Resverlogix Corp
 November 22 2024 Phase 1|Phase 2
NCT06377293 Not yet recruiting
End-Stage Kidney Disease
Far Eastern Memorial Hospital
 November 2024 Not Applicable
NCT06405555 Not yet recruiting
Heart Failure With Reduced Ejection Fraction|Hypotension|LV Dysfunction
Ottawa Heart Institute Research Corporation
 August 1 2024 Phase 2|Phase 3
NCT06398002 Not yet recruiting
Secondary Hyperparathyroidism|End-stage Kidney Disease
Iain Bressendorff|Herlev Hospital
 August 1 2024 Phase 2
NCT06383403 Not yet recruiting
Primary Biliary Cholangitis
Ipsen
 July 1 2024 Phase 3
NCT06095986 Not yet recruiting
Primary Sclerosing Cholangitis
Galmed Research and Development Ltd.|Virginia Commonwealth University|Galmed Pharmaceuticals Ltd
 June 2024 Phase 2

Chemical Information & Solubility

Molecular Weight 293.28 Formula
C16H11N3O3
CAS No. 237430-03-4 SDF --
Smiles C1C2=C(C3=CC=CC=C3NC1=O)NC4=C2C=C(C=C4)[N+](=O)[O-]
Storage (From the date of receipt) 3 years -20°C powder

In vitro
Batch:

DMSO : 25 mg/mL ( (85.24 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble

Ethanol : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Alsterpaullone | Alsterpaullone supplier | purchase Alsterpaullone | Alsterpaullone cost | Alsterpaullone manufacturer | order Alsterpaullone | Alsterpaullone distributor